Protocol CO-338-100. A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated with Deleterious Mutations in Homologous Recombination Repair Genes.
Single agent PARP inhibitor rucaparib for patients with a solid tumor that has a pathogenic alteration in any one of the following genes: BRCA1, BRCA2, PALB2, RAD51C, or RAD51D.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
Contact us today to request an appointment.Virtual & Telemedicine available.
Learn more news and information related to COVID-19.